Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Life Sciences Industry Analysis

UpdatedMar 14, 2026
DataAggregated Company Financials
Companies63
  • 7D-5.8%
  • 3M-19.8%
  • 1Y-11.0%
  • YTD-21.1%

Over the last 7 days, the Life Sciences industry has dropped 5.8%, driven by Thermo Fisher Scientific declining 7.5%. On the other hand Atlantic International is actually up 45%. The industry has fallen 11% in the last year. Looking forward, earnings are forecast to grow by 15% annually.

Industry Valuation and Performance

Has the U.S. Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 14 Mar 2026US$537.8bUS$147.8bUS$14.0b34.2x38.3x3.6x
Mon, 09 Feb 2026US$618.0bUS$147.4bUS$12.9b36.4x48.1x4.2x
Wed, 07 Jan 2026US$689.0bUS$145.8bUS$12.4b36.8x55.7x4.7x
Fri, 05 Dec 2025US$668.6bUS$145.8bUS$12.5b35.4x53.6x4.6x
Sun, 02 Nov 2025US$649.2bUS$145.4bUS$12.2b36x53.4x4.5x
Tue, 30 Sep 2025US$552.2bUS$144.3bUS$14.6b29.8x37.9x3.8x
Thu, 28 Aug 2025US$580.0bUS$144.1bUS$14.5b28.9x40x4x
Sat, 26 Jul 2025US$583.4bUS$143.6bUS$8.8b40.9x66.4x4.1x
Mon, 23 Jun 2025US$520.3bUS$142.9bUS$9.2b35.3x56.7x3.6x
Wed, 21 May 2025US$520.3bUS$142.8bUS$9.1b33.1x57.2x3.6x
Fri, 18 Apr 2025US$513.3bUS$142.6bUS$10.0b34.3x51.6x3.6x
Sun, 16 Mar 2025US$597.8bUS$143.1bUS$9.8b38.6x61.2x4.2x
Tue, 11 Feb 2025US$658.3bUS$143.1bUS$11.1b37.5x59.3x4.6x
Thu, 09 Jan 2025US$678.6bUS$142.4bUS$10.2b43.7x66.5x4.8x
Sat, 07 Dec 2024US$655.5bUS$142.4bUS$10.2b44.2x64.1x4.6x
Mon, 04 Nov 2024US$689.4bUS$142.2bUS$8.9b39.1x77.3x4.8x
Wed, 02 Oct 2024US$752.7bUS$141.8bUS$8.5b39.3x88.6x5.3x
Fri, 30 Aug 2024US$741.9bUS$141.8bUS$8.5b37.6x87.3x5.2x
Sun, 28 Jul 2024US$732.9bUS$141.0bUS$12.6b37.3x58.3x5.2x
Tue, 25 Jun 2024US$694.3bUS$141.3bUS$12.2b38.4x57x4.9x
Thu, 23 May 2024US$736.1bUS$141.5bUS$12.4b38.4x59.2x5.2x
Sat, 20 Apr 2024US$682.0bUS$142.0bUS$12.8b41x53.3x4.8x
Mon, 18 Mar 2024US$741.1bUS$142.1bUS$12.8b43.9x57.7x5.2x
Wed, 14 Feb 2024US$697.5bUS$142.2bUS$12.8b40.3x54.3x4.9x
Fri, 12 Jan 2024US$692.4bUS$153.9bUS$14.2b35.5x48.9x4.5x
Sun, 10 Dec 2023US$644.8bUS$153.7bUS$14.0b35.2x46x4.2x
Tue, 07 Nov 2023US$595.2bUS$153.9bUS$11.0b30.3x54x3.9x
Thu, 05 Oct 2023US$640.4bUS$154.6bUS$11.2b32.8x57.2x4.1x
Sat, 02 Sep 2023US$735.8bUS$154.6bUS$11.2b33.1x65.7x4.8x
Mon, 31 Jul 2023US$739.7bUS$154.7bUS$11.6b31.5x63.6x4.8x
Wed, 28 Jun 2023US$677.2bUS$152.4bUS$12.5b29.3x54.2x4.4x
Fri, 26 May 2023US$671.4bUS$152.2bUS$12.5b27.8x53.7x4.4x
Sun, 23 Apr 2023US$728.5bUS$154.6bUS$10.8b29.9x67.4x4.7x
Tue, 21 Mar 2023US$700.7bUS$154.5bUS$10.8b26.2x64.8x4.5x
Price to Earnings Ratio

64.8x


Total Market Cap: US$700.7bTotal Earnings: US$10.8bTotal Revenue: US$154.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Life Sciences Industry Price to Earnings3Y Average 58.1x202420252026
Current Industry PE
  • Investors are pessimistic on the American Life Sciences industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 38.3x which is lower than its 3-year average PE of 58.1x.
  • The 3-year average PS ratio of 4.5x is higher than the industry's current PS ratio of 3.6x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have grown 9.1% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market-1.64%
Healthcare-2.14%
Life Sciences-5.79%
Clinical Research and Equipment-5.79%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ATLN Atlantic InternationalUS$4.1844.6%
+US$96.9m		-15.4%PS0.7x
TKNO Alpha TeknovaUS$2.7932.2%
+US$36.4m		-50.0%PS3.7x
CDXS CodexisUS$1.6130.9%
+US$34.3m		-42.1%PS2.1x
QSI Quantum-SiUS$0.9510.2%
+US$19.0m		-30.2%PS84.3x
DNA Ginkgo Bioworks HoldingsUS$6.804.6%
+US$17.5m		-2.4%PS2.3x

Latest News

HYFT
US$1.24
MindWalk Holdings
7D
11.7%
1Y
222.2%
DNA
US$6.80
Ginkgo Bioworks Holdings
7D
4.6%
1Y
-2.4%

DNA: Future Returns Will Hinge On Monetizing Autonomous Labs By 2026

Analysts have trimmed their average price target for Ginkgo Bioworks Holdings, with cuts from $14 to $12 and from $9 to $5, reflecting reduced revenue growth assumptions, a slightly lower fair value estimate, and a higher discount rate as they wait for clearer progress on monetizing autonomous labs after the biosecurity divestiture. Analyst Commentary Bullish Takeaways Bullish analysts still see enough long term potential to maintain positive ratings, even as they trim price targets to US$12 from US$14.
CDXS
US$1.61
Codexis
7D
30.9%
1Y
-42.1%
ILMN
US$118.94
Illumina
7D
-4.6%
1Y
38.9%
CRL
US$155.46
Charles River Laboratories International
7D
-10.9%
1Y
-9.1%

A Company Preparing for the Future: Charles River Laboratories

The Hidden Bottleneck in Drug Development: Why Charles River Acquired a Cambodian Primate Supplier On January 12, 2026, Charles River Laboratories announced that it had signed an agreement to acquire the assets of K.F. (Cambodia) Ltd., a major non-human primate (NHP) breeding and supply company. [$510M] At first glance, this transaction might appear to be a routine supply chain acquisition in the contract research organization (CRO) industry.
QGEN
US$40.60
Qiagen
7D
-8.9%
1Y
-2.3%

QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns

The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.
TKNO
US$2.79
Alpha Teknova
7D
32.2%
1Y
-50.0%

TKNO: Updated Revenue Outlook Will Support Future Upside Potential

Analysts have trimmed their price target on Alpha Teknova to $7.00 from $7 as they factor in updated assumptions for the discount rate, revenue growth, profit margin and future P/E. Their view remains broadly aligned with prior estimates while they fine tune the model inputs.
A
US$111.51
Agilent Technologies
7D
-3.1%
1Y
-8.0%

A: New Diagnostic Approvals And Digital Pathology Expansion Will Drive Upside

Analysts have trimmed their price target on Agilent Technologies to about $163 from roughly $170, citing modest tweaks to their models, including slightly adjusted revenue growth, discount rate, profit margin, and future P/E assumptions. What's in the News Agilent issued earnings guidance for fiscal Q2 2026, with revenue expected in the range of $1.79b to $1.82b, framed as approximately 7% to 9% reported growth and 4% to 5.5% core growth (company guidance).
WAT
US$286.57
Waters
7D
-5.3%
1Y
-24.0%
ABCL
US$3.49
AbCellera Biologics
7D
1.2%
1Y
38.5%

ABCL: Patent Settlement And Menopause Trial Will Support A Stronger Outlook

Analysts have lowered their price target on AbCellera Biologics from $15.88 to $12.00, reflecting updated views on fair value, revenue growth expectations, and future P/E assumptions. What's in the News The first patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).
TMO
US$464.37
Thermo Fisher Scientific
7D
-7.5%
1Y
-11.0%

TMO: 2026 Tools Recovery And AI Use In Labs Will Support Upside

Analysts have raised their consolidated price target for Thermo Fisher Scientific by about $25, citing updated expectations for steady mid single digit organic growth into 2026, modestly higher profit margins and a slightly lower future P/E multiple. Analyst Commentary Recent street research points to a cluster of higher price targets for Thermo Fisher Scientific, with several bullish analysts updating their models to reflect expectations for mid single digit organic growth into 2026, slightly stronger margins and an adjusted P/E framework.
QSI
US$0.95
Quantum-Si
7D
10.2%
1Y
-30.2%
DHR
US$187.32
Danaher
7D
-4.2%
1Y
-11.1%

DHR: Masimo Cash Deal Will Support Re Rating And Premium Multiple

The analyst price target for Danaher has moved higher by a mid single digit dollar amount, reflecting updated assumptions for slightly stronger revenue growth and margins, alongside recent Street research that raised targets following the Masimo acquisition announcement and sector wide target adjustments. Analyst Commentary Recent Street research around Danaher reflects a mix of optimism on the Masimo acquisition and valuation, alongside a more cautious stance on deal terms and execution risk.
IQV
US$164.72
IQVIA Holdings
7D
-5.6%
1Y
-11.1%

IQV: Future Returns Will Balance Trial Upside With AI And Execution Risks

Analysts have trimmed their fair value estimate for IQVIA Holdings from about $223 to roughly $186, reflecting a shift to a lower assumed future P/E multiple and a slightly higher discount rate. They still see upside potential based on expected clinical trial activity and the company's data analytics capabilities.
MXCT
US$0.82
MaxCyte
7D
4.8%
1Y
-75.1%
ATLN
US$4.18
Atlantic International
7D
44.6%
1Y
-15.4%